Positive reinforcement targeting abstinence in substance misuse

ISRCTN ISRCTN01591254
DOI https://doi.org/10.1186/ISRCTN01591254
Secondary identifying numbers 6113
Submission date
19/11/2012
Registration date
19/11/2012
Last edited
05/07/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Some people being receiving opioid substitution treatment (OST) with drugs like methadone, subutex, or suboxone either drop out of treatment early or continue to use heroin. Researchers in the USA have found that drug treatment clinics can help service users stay in treatment and reduce their heroin use by offering them shop vouchers. We call this positive reinforcement or contingency management (CM). Contingency Management has a strong evidence base in the US and has been recommended by National Institute for Health and Clinical Excellence (NICE) for UK implementation. However, the UK has little track record of applying contingency management in drug treatment. To find out if positive reinforcement might be helpful in reducing use of street heroin among opiate users receiving OST here in the UK, the aim of this study is to compare providing usual OST (methadone or subutex) to providing usual treatment with positive reinforcement.

Who can participate?
Heroin users, men and women, aged over 18 years, presenting to drug clinics for opiate treatment

What does the study involve?
The participating clinics are randomly allocated to one of three treatments: usual treatment (OST plus key work sessions), usual treatment plus positive reinforcement of attendance or usual treatment plus positive reinforcement of abstinence. Incentives are vouchers exchangeable for goods/services. After week 12, the contingency management is stopped and all participants receive only usual care. Urine samples are collected at various stages of the study. The practical problems encountered in recruiting sites, clinical staff and patients to this trial are examined.

What are the possible benefits and risks of participating?
There are no immediate benefits from taking part. Participants have a chance of receiving shop vouchers for attending interviews and key work sessions or providing urine samples negative for heroin. Participants involvement in the research could help improve the care provided at drug treatment clinics. The information from this research could help improve opiate treatment programmes in the future. However, participants may be asked to attend more key work sessions and provide more urine samples than usual.

Where is the study run from?
Institute of Psychiatry, King's College London (UK)

When is the study starting and how long is it expected to run for?
November 2012 to April 2014

Who is funding the study?
National Institute for Health Research (NIHR) (UK)

Who is the main contact?
Dr Nicola Metrebian
nicola.metrebian@kcl.ac.uk

Contact information

Dr Nicola Metrebian
Scientific

Addictions Department
Institute of Psychiatry
King's College London
4 Windsor Walk
Denmark Hill
London
SE5 8AF
United Kingdom

Email nicola.metrebian@kcl.ac.uk

Study information

Study designMulti-centre stratified cluster randomised trial
Primary study designInterventional
Secondary study designCluster randomised trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleCluster randomised controlled trial of two Contingency Management schedules targeting treatment attendance or abstinence from street heroin use in people treated for heroin dependence
Study acronymPRAISe
Study objectivesContingency Management (CM) is a psychological intervention using positive reinforcement (usually in the form of praise and vouchers which can be exchangeable for goods) to encourage engagement with treatment and to promote behaviours congruent with treatment goals. This intervention is delivered as an adjunct to existing opiate substitute treatment.

The aim of this trial is to implement, observe and assess the acceptability, feasibility and clinical and cost effectiveness of Contingency Management (CM) strategies to improve treatment attendance and abstinence from heroin.
Ethics approval(s)NRES Committee South East Coast - Surrey, 25/07/2012, ref: 12/LO/0910
Health condition(s) or problem(s) studiedMental Health Research Network; Addictions
InterventionEach of the 33 clinics will be their own cluster. Each clinic/cluster will be randomly assigned to one of the following trial arms (i.e., 20 participants per cluster, 11 clusters per arm, 220 participants in each arm and 660 in total):
1. TAU + 12 week schedule of weekly keywork appointments (no praise or voucher)
2. TAU + 12 week positive reinforcement (praise and voucher) for attending scheduled weekly keywork appointments
3. TAU + 12 week positive reinforcement (praise and voucher) for providing a weekly urine sample negative for opiates
Both CM schedules will offer the same valve of incentive over a 12 week period, but with different target behaviours (attendance vs abstinence). Incentives will be vouchers exchangeable at general supermarket chains.

Results are compared for the primary outcome at the 3rd month (weeks 9-12) in all three treatment conditions. The outcome of the trial will be determined by the mean number of urine tests results negative for opiates during weeks 9-12. After week 12, there will be complete cessation of rewards. In the follow-up phase (weeks 13-24) all participants will receive identical care with no CM. All primary and secondary outcomes at 12 weeks will be reassessed at 24 weeks for all participants. In addition, the number of opiate-negative urine test results during weeks 21-24 will be assessed.

The trial data will also be used to model differential costs of the two CM schedules vs current practice. A process evaluation will be conducted alongside the trial, in order to understand the implementation, delivery, fidelity and outcome of the trial intervention.
Intervention typeOther
Primary outcome measureMean number of opiate negative urine test results during weeks 9-12
Secondary outcome measures1. Retention in treatment at the 3-month and 6-month follow-up
2. Urine test results at the 6-month follow-up (3 months post-CM)
3. Indices of physical, psychological and social well-being
4. Health economic and criminal justice outcomes
Overall study start date12/11/2012
Completion date30/04/2014

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsUK Sample Size: 660; Description: 33 clusters each with 20 participants
Total final enrolment552
Key inclusion criteria1. Aged >18 years
2. Seeking new episode of OST treatment
3. Agree to 12 week treatment programme promoting abstinence
4. Regular users of street heroin in preceding month (self report 15/30 use and all UDS in past 4 weeks opiate positive)
5. Opiate dependent (meeting ICD-10 criteria) and at liberty to participate in the study for 24 weeks
6. Willing and able to provide informed consent
7. Male or female
Key exclusion criteria1. Pregnant or breastfeeding
2. Active mental health problem
3. Patients referred into treatment under a criminal justice order
4. Patients who cannot read English AND require the service of an interpreter to understand a brief oral description of the study
Date of first enrolment19/11/2012
Date of final enrolment30/04/2014

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

King's College London
London
SE5 8AF
United Kingdom

Sponsor information

South London & Maudsley NHS Foundation Trust and Kings College London (UK)
Hospital/treatment centre

c/o Ms Jenny Liebscher
SLaM R&D Office
Room W1.08
Institute of Psychiatry
De Crespigny Park
Denmark Hill
London
SE5 8AF
England
United Kingdom

Website http://www.slam.nhs.uk/
ROR logo "ROR" https://ror.org/015803449

Funders

Funder type

Government

NIHR Programme Grants for Applied Research ref: RP-PG-0707-10149 (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 01/08/2018 Yes No
Results article 01/07/2021 05/07/2021 Yes No

Editorial Notes

05/07/2021: The following changes have been made:
1. Publication reference added.
2. The final enrolment number has been added from the reference.
26/10/2020: The recruitment start date was changed from 12/11/2012 to 19/11/2012.
07/08/2020: Internal review.
19/06/2018: Publication reference added.
24/01/2017: No publications found, verifying study status with principal investigator.